Implementation of tuberculosis (TB) services for children living with HIV in US President's Emergency Plan for AIDS Relief-supported programs in 16 high TB/HIV-burden countries in sub-Saharan Africa

在撒哈拉以南非洲16个结核病/艾滋病高负担国家,美国总统艾滋病紧急救援计划支持的项目中,为感染艾滋病毒的儿童实施结核病服务

阅读:3

Abstract

INTRODUCTION: We assessed implementation of tuberculosis (TB) services among children living with HIV (CLHIV) (<15 years) in 16 African countries supported by US President's Emergency Plan for AIDS Relief (PEPFAR) between October 2018 and September 2022 [fiscal year (FY) 2019-FY2022). METHODS: We reviewed PEPFAR TB indicators describing symptom screening, treatment initiation, and TB preventive treatment (TPT) initiation and completion among CLHIV. We describe performance of these measures at semi-annual time points from FY2019 to FY2022 with stratification by age, sex, geographic region, and antiretroviral therapy (ART) status for FY2022. RESULTS: During FY2019-FY2022, the proportion of CLHIV with a positive TB symptom screen was low, ranging from 2.5 to 4.1%, while TB treatment initiation among those who screened positive fluctuated from 19 to 43%. Similarly, TPT initiation among CLHIV newly initiating ART fluctuated during this time, ranging from 13 to 37%, while TPT completion rose from 55 to 85%. In 2022, 80% of CLHIV were screened for TB and 3.6% had a positive symptom screen. Among those, 15% of CLHIV already on ART and 40% of CLHIV newly initiating ART were started on TB treatment. In 2022, among CLHIV newly initiating ART, 37% started TPT within 6 months, and 84% completed the full course of TPT. CONCLUSION: TB screening and screening positivity were suboptimal. CLHIV starting TB treatment following positive symptom screen was higher than expected, especially among those newly initiating ART. Most CLHIV did not start TPT within 6 months of ART initiation. These findings suggest that programs are missing opportunities to diagnose and prevent TB in CLHIV.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。